Summary
13.66 0.32(2.36%)10/04/2024
AxoGen Inc (AXGN)
AxoGen Inc (AXGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.28 | -0.91 | 4.56 | 80.62 | 75.97 | 184.48 | 13.51 | 319.46 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 13.66 | |
| Open | 13.49 | |
| High | 13.81 | |
| Low | 13.33 | |
| Volume | 166,486 | |
| Change | 0.31 | |
| Change % | 2.28 | |
| Avg Volume (20 Days) | 296,941 | |
| Volume/Avg Volume (20 Days) Ratio | 0.56 | |
| 52 Week Range | 3.45 - 15.08 | |
| Price vs 52 Week High | -9.45% | |
| Price vs 52 Week Low | 295.80% | |
| Range | 1.22 | |
| Gap Up/Down | -0.61 | |
Fundamentals | ||
| Market Capitalization (Mln) | 605 | |
| EBIDTA | -13,388,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 12.67 | |
| Book Value | 2.1320 | |
| Earnings Per Share | -0.4900 | |
| EPS Estimate Current Quarter | -0.0700 | |
| EPS Estimate Next Quarter | -0.0500 | |
| EPS Estimate Current Year | -0.1300 | |
| EPS Estimate Next Year | 0.1700 | |
| Diluted EPS (TTM) | -0.4900 | |
| Revenues | ||
| Profit Marging | -0.1300 | |
| Operating Marging (TTM) | -0.1102 | |
| Return on asset (TTM) | -0.0621 | |
| Return on equity (TTM) | -0.2232 | |
| Revenue TTM | 163,726,000 | |
| Revenue per share TTM | 3.8040 | |
| Quarterly Revenue Growth (YOY) | 0.1290 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 114,437,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.2949 | |
| Revenue Enterprise Value | 2.2229 | |
| EBITDA Enterprise Value | -26.5212 | |
| Shares | ||
| Shares Outstanding | 43,704,600 | |
| Shares Float | 33,867,548 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 5.22 | |
| Institutions (%) | 75.61 | |
09/23 16:06 EST - zacks.com
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
09/06 07:00 EST - globenewswire.com
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®.
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®.
09/04 10:16 EST - zacks.com
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
08/30 13:01 EST - zacks.com
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now?
Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now?
Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
08/23 10:55 EST - zacks.com
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?
The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?
The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
08/19 10:15 EST - zacks.com
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
08/08 14:10 EST - seekingalpha.com
Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports 2024 Second Quarter Financial Results Call. At this time all participants are in a listen-only mode.
Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports 2024 Second Quarter Financial Results Call. At this time all participants are in a listen-only mode.
08/08 09:21 EST - zacks.com
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.
08/08 07:05 EST - globenewswire.com
Axogen, Inc. Announces New Leadership Appointments
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months.
Axogen, Inc. Announces New Leadership Appointments
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months.
08/01 11:06 EST - zacks.com
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/23 07:00 EST - globenewswire.com
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
07/12 09:41 EST - zacks.com
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
07/01 07:00 EST - globenewswire.com
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee.
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee.
06/25 13:55 EST - zacks.com
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
06/24 07:00 EST - globenewswire.com
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrixâ„¢
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product.
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrixâ„¢
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product.
06/12 06:01 EST - zacks.com
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
05/28 16:30 EST - globenewswire.com
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth Showcasing Axogen's Dedication to Fueling Ohio's Biotechnology Sector Growth
05/17 13:31 EST - zacks.com
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
05/05 01:21 EST - seekingalpha.com
AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Harold Tamayo - VP, Finance and IR Karen Zaderej - Chairman, CEO and President Nir Naor - CFO Conference Call Participants Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Greetings, and welcome to the AxoGen, Inc. 2024 First Quarter Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
05/02 09:16 EST - zacks.com
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago.